Clinical Trials Logo

Filter by:
NCT ID: NCT02251275 Completed - Clinical trials for Polycystic Kidney, Autosomal Dominant

Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Start date: October 17, 2014
Phase: Phase 3
Study type: Interventional

The purpose of the trial was to evaluate and describe the long term safety of tolvaptan in participants with autosomal dominant polycystic kidney disease (ADPKD).

NCT ID: NCT02250859 Completed - Acne Clinical Trials

A Pharmacokinetic Study of Minocycline in Male and Female Volunteers

Start date: September 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the pharmakokinetic profile of Minocycline in FMX-101 4% foam product in male and female some of which are with acne

NCT ID: NCT02250742 Completed - Low Back Pain Clinical Trials

The Effect of Dry Needling on Trunk Muscle Function in Low Back Pain Patients

Start date: September 2014
Phase: N/A
Study type: Interventional

The study will establish data on the function of trunk muscles in healthy and low back pain patient's pre and post dry needling treatment. This will help in understanding the underlying mechanism of this treatment and reveal the effect of dry needling on muscle performance. Study hypothesis is that an improvement of back muscle function following dry needling procedure will be found.

NCT ID: NCT02250508 Completed - Clinical trials for vonWillebrand's Disease

A Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With Von Willebrand Disease.

Start date: December 2004
Phase: Phase 2
Study type: Interventional

The main objectives of the study were - to compare the pharmacokinetics (PK) of Optivate® and Haemate P® in various types of vonWillebrand disease (VWD) using the results from the VWF: RCo, VWF:Ag, VWF:CBA and Factor VIII assays. - to compare the clinical tolerance and safety of these two treatments after single IV infusions in subjects with VWD.

NCT ID: NCT02249429 Completed - Lymphoma, Malignant Clinical Trials

Open-Label, Non Randomized Phase 2 Study With Safety Run-In

Start date: May 2015
Phase: Phase 2
Study type: Interventional

The main goal of this study is to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D) as well as preliminary antitumor activity of bimiralisib (PQR309) administered orally, as once daily capsules continuously and on intermittent schedule in patients with relapsed or refractory lymphomas.

NCT ID: NCT02247804 Completed - Ocular Hypertension Clinical Trials

Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension

Start date: December 15, 2014
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of bimatoprost SR in participants with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.

NCT ID: NCT02247622 Recruiting - Clinical trials for Inflammatory Bowel Disease

Telomere Length and Other Parameters of Telomere Dysfunction in PSC and Colitis

Start date: February 2012
Phase: N/A
Study type: Observational

PSC is a chronic cholestatic disorder. The investigators intend to study some telomere parameters and telomere length in order to predict a premalignant state.

NCT ID: NCT02247102 Recruiting - Malabsorption Clinical Trials

Investigate the Breath Hydrogen Exhalation After a Test Meal Containing Isomaltulose or Sucrose in Infants

Start date: September 2014
Phase: Phase 3
Study type: Interventional

The study shall investigate whether isomaltulose - is digested and absorbed to a comparable degree like other carbohydrates (CHO) used as ingredients for this age group (e.g. sucrose), by measuring the H2 exhalation in the postprandial period - does not mediate abdominal discomfort or diarrhoea and is therefore as well tolerated as other CHO (e.g. sucrose), by/in healthy infants aged 6 to 12 months. It is hypothesized that isomaltulose, provided with a standard follow-on formula, 1. will not significantly increase the mean basal breath H2-excretion rate (determined as the incremental area under the curve (iAUC) of H2-exhalation) over a 3 h postprandial period compared to a sucrose containing standard follow-on formula. 2. will not lead to a significantly different gastrointestinal tolerance in the conse-quent 24 h after formula consumption compared to a sucrose containing standard follow-on formula in infants aged 6 to 12 months.

NCT ID: NCT02246621 Active, not recruiting - Breast Cancer Clinical Trials

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

MONARCH 3
Start date: November 6, 2014
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to evaluate how effective nonsteroidal aromatase inhibitors (NSAI) plus abemaciclib are in postmenopausal women with breast cancer. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio.

NCT ID: NCT02246517 Not yet recruiting - Neuropathic Pain Clinical Trials

The Effect of N2O on Chronic Neuropathic Pain Patients

N2O
Start date: September 2014
Phase: Phase 0
Study type: Interventional

Important pharmacological agents for treatment of chronic neuropathic pain such as ketamine block NMDA receptors. Nitrous oxide, an inhalant agent used extensively In anesthesia, also have antagonist property of NMDA receptors. The investigators hypothesize that prolonged treatment with N2O can alleviate chronic neuropathic pain of different causes (e.g. diabetic neuropathy, post herpetic neuralgia etc.).